Intravenous calcium for the prevention of postpartum hemorrhage in cesarean delivery: A systematic review and meta-analysis.

Eur J Obstet Gynecol Reprod BiolJul 9, 2026 (epub)
Clinical ResearchObstetrics & Gynecology

Camila M Aihara Nakayama, Laura Beatriz Wuensch Weschenfelder, Maria Julia Lemos et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy of intravenous calcium in preventing postpartum hemorrhage during cesarean deliveries, involving 746 patients across six trials. The findings suggest a statistically significant reduction in blood loss (WMD = -46.36 mL) and intravenous fluid requirements (WMD = -52.44 mL), alongside a reduced need for second-line uterotonics (RR = 0.64).

Key findings

  • Blood loss was reduced by 46.36 mL with intravenous calcium (p < 0.0001).
  • Intravenous fluid requirements decreased by 52.44 mL (p = 0.0006).
  • The need for second-line uterotonics was reduced with a risk ratio of 0.64 (p = 0.02).

Why it matters

Understanding the role of intravenous calcium in cesarean deliveries can help clinicians make informed decisions regarding the management of postpartum hemorrhage, potentially improving patient outcomes.

Source

PubMed · PMID 42447778

Published in Eur J Obstet Gynecol Reprod Biol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.